New drug AVP-786 passes first safety check in healthy people
NCT ID NCT02174835
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new drug, AVP-786, in 56 healthy adult men to see how the body processes it and whether it is safe. The drug is a modified version of dextromethorphan combined with quinidine. Because this is a Phase 1 study in healthy people, it does not test whether the drug works for any disease, but it is a necessary first step before testing in patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AVP-786 (deuterated dextromethorphan/quinidine)
What this could lead to
If successful, this early study could support further testing of AVP-786 for conditions like agitation in Alzheimer's disease.
What could go wrong
This is a very early Phase 1 trial in only 56 healthy volunteers, so it cannot prove the drug works for any disease. Side effects or lack of benefit may emerge in later studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CMAX
Adelaide, South Australia, 5000, Australia